Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCERNE: Phase III Study of Faricimab in Neovascular Age-related Macular Degeneration (China Extension)
CTR20190936Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in exudative macular degeneration, sponsored by Roche. Started Jan 2020; status: completed.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20190936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190936.